Please login to the form below

Not currently logged in
Email:
Password:

Waldenstrom's macroglobulinaemia

This page shows the latest Waldenstrom's macroglobulinaemia news and features for those working in and with pharma, biotech and healthcare.

Janssen's Imbruvica fails to win NICE backing in lymphoma

Janssen's Imbruvica fails to win NICE backing in lymphoma

There was some positive news for Janssen, however, as Imbruvica received a positive recommendation to treat Waldenström's Macroglobulinaemia (WM) in adults who have had at least one prior therapy.

Latest news

  • NICE rejects Imbruvica for non-Hodgkin’s lymphoma NICE rejects Imbruvica for non-Hodgkin’s lymphoma

    Draft guidance cites insufficient cost-effectiveness evidence for J&J’s drug. NICE has once again rejected Johnson &Johnson's Imbruvica (ibrutinib) for use on the NHS in England and Wales, ... Imbruvica is used to treat Waldenstrom's macroglobulinaemia

  • FDA clears Imbruvica as chemo alternative for first-line CLL FDA clears Imbruvica as chemo alternative for first-line CLL

    mantle cell lymphoma (MCL) and the treatment of Waldenström's macroglobulinaemia. ... AbbVie and J&J's drug also achieved partial or complete responses in 82% of patients, compared to 35% of the chemotherapy group.

  • AZ takes majority stake in cancer drug developer Acerta AZ takes majority stake in cancer drug developer Acerta

    Acalabrutinib is a Bruton's tyrosine kinase (Btk) inhibitor in the same class as Janssen/Pharmacyclics/Abbvie's Imbruvica (ibrutinib) drug for chronic lymphocytic leukaemia (CLL) and Waldenström's macroglobulinaemia, which ... This week it agreed a

  • AZ confirms interest in Acerta takeover AZ confirms interest in Acerta takeover

    as a treatment for chronic lymphocytic leukaemia (CLL) and Waldenström's macroglobulinaemia. . ... Analysts have speculated that AZ's interest in Acerta could draw other possible suitors out of the shadows.

  • Imbruvica filed as first-line leukaemia therapy Imbruvica filed as first-line leukaemia therapy

    of Waldenström's macroglobulinaemia. ... The drug still has a long way to go however to meet its $10bn-plus peak sales target - and also justify AbbVie's $21bn purchase of Pharmacyclics earlier this year - and

More from news
Approximately 1 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics